Protalix BioTherapeutics utilizes its proprietary plant cell-based expression system to develop recombinant therapeutic proteins for treating rare, complex genetic disorders. Its flagship commercial applications include enzyme replacement therapies designed to treat conditions like Fabry disease, addressing severe metabolic deficiencies through advanced biotherapeutic protein structures produced safely in plant cell cultures.